BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 24111611)

  • 1. Genetics on a WHIM.
    Al Ustwani O; Kurzrock R; Wetzler M
    Br J Haematol; 2014 Jan; 164(1):15-23. PubMed ID: 24111611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and genetic features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome.
    Dotta L; Tassone L; Badolato R
    Curr Mol Med; 2011 Jun; 11(4):317-25. PubMed ID: 21506920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.
    McDermott DH; Liu Q; Ulrick J; Kwatemaa N; Anaya-O'Brien S; Penzak SR; Filho JO; Priel DA; Kelly C; Garofalo M; Littel P; Marquesen MM; Hilligoss D; Decastro R; Fleisher TA; Kuhns DB; Malech HL; Murphy PM
    Blood; 2011 Nov; 118(18):4957-62. PubMed ID: 21890643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plerixafor on a WHIM - Promise or Fantasy of a New CXCR4 Inhibitor for This Rare, but Important Syndrome?
    Merati N; Sivachandran S; Jfri A; Ben-Shoshan M; Vinh DC; Popradi G; Litvinov IV
    Skin Therapy Lett; 2022 Mar; 27(2):1-5. PubMed ID: 35385630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetralogy of fallot is an uncommon manifestation of warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
    Badolato R; Dotta L; Tassone L; Amendola G; Porta F; Locatelli F; Notarangelo LD; Bertrand Y; Bachelerie F; Donadieu J
    J Pediatr; 2012 Oct; 161(4):763-5. PubMed ID: 22748845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome.
    McDermott DH; Velez D; Cho E; Cowen EW; DiGiovanna JJ; Pastrana DV; Buck CB; Calvo KR; Gardner PJ; Rosenzweig SD; Stratton P; Merideth MA; Kim HJ; Brewer C; Katz JD; Kuhns DB; Malech HL; Follmann D; Fay MP; Murphy PM
    J Clin Invest; 2023 Oct; 133(19):. PubMed ID: 37561579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plerixafor for the Treatment of WHIM Syndrome.
    McDermott DH; Pastrana DV; Calvo KR; Pittaluga S; Velez D; Cho E; Liu Q; Trout HH; Neves JF; Gardner PJ; Bianchi DA; Blair EA; Landon EM; Silva SL; Buck CB; Murphy PM
    N Engl J Med; 2019 Jan; 380(2):163-170. PubMed ID: 30625055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How I treat warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
    Badolato R; Donadieu J;
    Blood; 2017 Dec; 130(23):2491-2498. PubMed ID: 29066537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WHIM syndrome: Immunopathogenesis, treatment and cure strategies.
    McDermott DH; Murphy PM
    Immunol Rev; 2019 Jan; 287(1):91-102. PubMed ID: 30565238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AMD3100 is a potent antagonist at CXCR4(R334X) , a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome.
    McDermott DH; Lopez J; Deng F; Liu Q; Ojode T; Chen H; Ulrick J; Kwatemaa N; Kelly C; Anaya-O'Brien S; Garofalo M; Marquesen M; Hilligoss D; DeCastro R; Malech HL; Murphy PM
    J Cell Mol Med; 2011 Oct; 15(10):2071-81. PubMed ID: 21070597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.
    McDermott DH; Liu Q; Velez D; Lopez L; Anaya-O'Brien S; Ulrick J; Kwatemaa N; Starling J; Fleisher TA; Priel DA; Merideth MA; Giuntoli RL; Evbuomwan MO; Littel P; Marquesen MM; Hilligoss D; DeCastro R; Grimes GJ; Hwang ST; Pittaluga S; Calvo KR; Stratton P; Cowen EW; Kuhns DB; Malech HL; Murphy PM
    Blood; 2014 Apr; 123(15):2308-16. PubMed ID: 24523241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCR4-Specific Nanobodies as Potential Therapeutics for WHIM syndrome.
    de Wit RH; Heukers R; Brink HJ; Arsova A; Maussang D; Cutolo P; Strubbe B; Vischer HF; Bachelerie F; Smit MJ
    J Pharmacol Exp Ther; 2017 Oct; 363(1):35-44. PubMed ID: 28768817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A WHIM satisfactorily addressed.
    Broxmeyer HE
    Blood; 2014 Apr; 123(15):2286-8. PubMed ID: 24723677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.
    Dale DC; Bolyard AA; Kelley ML; Westrup EC; Makaryan V; Aprikyan A; Wood B; Hsu FJ
    Blood; 2011 Nov; 118(18):4963-6. PubMed ID: 21835955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive Immunodeficiency in WHIM Syndrome.
    Majumdar S; Murphy PM
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease Progression of WHIM Syndrome in an International Cohort of 66 Pediatric and Adult Patients.
    Geier CB; Ellison M; Cruz R; Pawar S; Leiss-Piller A; Zmajkovicova K; McNulty SM; Yilmaz M; Evans MO; Gordon S; Ujhazi B; Wiest I; Abolhassani H; Aghamohammadi A; Barmettler S; Bhar S; Bondarenko A; Bolyard AA; Buchbinder D; Cada M; Cavieres M; Connelly JA; Dale DC; Deordieva E; Dorsey MJ; Drysdale SB; Ehl S; Elfeky R; Fioredda F; Firkin F; Förster-Waldl E; Geng B; Goda V; Gonzalez-Granado L; Grunebaum E; Grzesk E; Henrickson SE; Hilfanova A; Hiwatari M; Imai C; Ip W; Jyonouchi S; Kanegane H; Kawahara Y; Khojah AM; Kim VH; Kojić M; Kołtan S; Krivan G; Langguth D; Lau YL; Leung D; Miano M; Mersyanova I; Mousallem T; Muskat M; Naoum FA; Noronha SA; Ouederni M; Ozono S; Richmond GW; Sakovich I; Salzer U; Schuetz C; Seeborg FO; Sharapova SO; Sockel K; Volokha A; von Bonin M; Warnatz K; Wegehaupt O; Weinberg GA; Wong KJ; Worth A; Yu H; Zharankova Y; Zhao X; Devlin L; Badarau A; Csomos K; Keszei M; Pereira J; Taveras AG; Beaussant-Cohen SL; Ong MS; Shcherbina A; Walter JE
    J Clin Immunol; 2022 Nov; 42(8):1748-1765. PubMed ID: 35947323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Periodontal disease in patients with WHIM syndrome.
    Brenchley L; McDermott DH; Gardner PJ; Silva LM; Gao JL; Cho E; Velez D; Moutsopoulos NM; Murphy PM; Fraser D
    J Clin Periodontol; 2024 Apr; 51(4):464-473. PubMed ID: 38185798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Late diagnosis of WHIM sydrome].
    Paolini MV; Danielian S; Prieto E; Tami MF; Oleastro MM; Fernández Romero DS
    Medicina (B Aires); 2018; 78(2):123-126. PubMed ID: 29659363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WHIM Syndrome With a Novel CXCR4 Variant in a Korean Child.
    Shin DW; Park SN; Kim SM; Im K; Kim JA; Hong KT; Choi JY; Hong CR; Park KD; Shin HY; Kang HJ; Kim HK; Lee DS
    Ann Lab Med; 2017 Sep; 37(5):446-449. PubMed ID: 28643496
    [No Abstract]   [Full Text] [Related]  

  • 20. Familial occurrence of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome.
    Siedlar M; Rudzki Z; Strach M; Trzyna E; Pituch-Noworolska A; Błaut-Szlósarczyk A; Bukowska-Strakova K; Lenart M; Grodzicki T; Zembala M
    Arch Immunol Ther Exp (Warsz); 2008; 56(6):419-25. PubMed ID: 19043667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.